Community Health Media

In this in-depth conversation, Dr. Jason Mouabbi, Dr. Joyce O’Shaughnessy, and Dr. Mothaffar Rimawi unpack the data that may redefine first-line treatment for HER2-positive metastatic breast cancer. From DESTINY-Breast 09 to real-world decision-making, they discuss what a 40-month median PFS truly means, how T-DXd compares to THP, and whether “if it ain’t broke, don’t fix it” still applies. They a...

Recorded live at ESMO 2025 in Berlin, this expert roundtable features Drs. Adam Brufsky, VK Gadi, Ian Krop, Neil Iyengar, Paolo Tarantino, Giancarlo Moscol, Shanu Modi, and Maryam Lustberg as they tackle the most pressing questions shaping breast cancer care today. From HER2-low and ultra-low disease to antibody–drug conjugates, trial interpretation, sequencing strategies, and what truly defines “...

Triple-negative breast cancer has entered a new era. At ESMO 2025, TRO-Breast02 and ASCENT-03 delivered practice-shifting data — from rapid progressors to PD-L1–defined pathways and the growing role of TROP2-targeted ADCs. Dr. Neil Iyengar and Dr. Erika Hamilton break down trial design differences, crossover implications, toxicity management, and how these results will shape first-line treatment d...

The landscape of HER2+ and HER2-low breast cancer is shifting fast — and DB-05 and DB-11 are at the center of it. In this deep-dive from ESMO 2025, Dr. Gregory Vidal and Dr. Erika Hamilton break down what the latest T-DXd data means for real-world practice, how ILD should be monitored, and why sequencing matters more than ever. #BreastCancer #HER2 #HER2Low #TDXd #TrastuzumabDeruxtecan #ESMO2025 #D...

At ESMO Berlin, Dr. Mark Pegram and Dr. Ana Garrido-Castro break down breakthrough data shaping the new standard for first-line metastatic triple-negative breast cancer (TNBC). Together, they unpack results from ASCENT-03 and TROPION-Breast02, where Trop-2 antibody-drug conjugates demonstrated significant improvements in response rates, PFS, and — in one study — overall survival. Drs. Pegram and G...

Achieving pCR has long been considered the “holy grail” in HER2+ breast cancer — but does it truly guarantee protection from recurrence, especially in the brain? In this conversation, Drs. Jason Mouabbi, Irene Kang, and Ruemu Birhiray explore evolving perspectives on pCR, CNS relapse, and the emerging role of neratinib in protecting high-risk patients. They discuss new data, the unmet need for CNS...

From testing to treatment, the conversation around PARP inhibition in breast cancer is rapidly evolving. In this episode, Dr. Neil Iyengar and Dr. Mark Robson explore how germline testing, risk stratification, and therapy sequencing are shaping adjuvant treatment decisions for BRCA1/2-mutated breast cancer. They discuss: 🔹 Who should be tested — and how testing criteria are expanding. 🔹 Key take...

Direct from ESMO 2025 in Berlin, Dr. Mark Pegram and Dr. Neil Iyengar unpack what many are calling a new standard in HER2-directed therapy. From DESTINY-Breast 11’s practice-changing neoadjuvant results to DESTINY-Breast 05 in the adjuvant setting — and now DESTINY-Breast 09 rewriting the metastatic playbook — the data are clear: trastuzumab deruxtecan (T-DXd) is transforming treatment across dise...

Watch this enlightening conversation focused on the transforming power of antibody-drug conjugates (ADCs) like T-DXd (trastuzumab deruxtecan) in HER2-positive breast cancer therapy with Dr. Anne O’Dea and Dr. VK Gadi. The doctors provide hope for T-DXd’s potential usage as a first-line treatment, which could change present guidelines away from conventional chemotherapy treatments like the Cleopatr...

Join Dr. VK Gadi and Dr. Jason Mouabbi at a recent conference for their discussion around the changing function of antibody-drug conjugates (ADCs) such as T-DXd (trastuzumab deruxtecan) in treating HER2-positive breast cancer, especially in patients with central nervous system (CNS) metastases. The talk hinges on the historical use of tiny compounds like tucatinib to ensure they’re able to pass th...

What happens when MD Anderson’s translational firebrand Jason Mouabbi sticks a microphone in front of long-time HER2 guru Mothaffar Rimawi just days after the first read-out of DESTINY-Breast09? In sixty candid minutes they chart how trastuzumab deruxtecan (T-DXd) ± pertuzumab vaulted past CLEOPATRA; posting a headline 41-month PFS that forces oncologists to rethink induction/maintenance dogma, se...

What happens when an MD Anderson breast oncology investigator Dr. Mouabbi sits down with a high-volume community oncologist Dr. Cairo, who now treats the same patients the trials were written for? Over one fast-moving hour, they chart the collapse of the old HER2 binary, weigh DESTINYBreast 04 against 06, and admit that practicing oncologists still hesitate to jump straight from endocrine therapy...

When the binary “HER2-positive vs HER2-negative” model collapsed under the weight of DESTINY-Breast04 and 06, the real work began: deciding who should receive trastuzumab deruxtecan (T-DXd), when to leapfrog chemotherapy, and how to keep quality of life front-and-center. In this interactive Live from Seattle stream, translational researcher & clinician Dr. V.K. Gadi and high-volume breast onco...

In this insightful CHM Conversations episode, Drs. Callahan & Bardia delve deep into the evolving definitions of HER2 positivity (and negativity, or lack of HER2) in breast cancer and the transformative impact of trastuzumab deruxtecan (T-DXd) especially in metastatic cases. From groundbreaking historical discoveries to recent clinical trial advancements, they critically examine how HER2 class...

In this episode of CHM Conversations, two of breast oncology’s brightest specialists — Dr. Jason Mouabbi and Dr. Paolo Tarantino — explore how trastuzumab deruxtecan (T-DXd) has fundamentally restructured therapeutic strategies across HER2-positive and HER2-low disease, while “curing” what was once thought to be really aggressive disease. From the transformative DESTINY-Breast trials to the evolvi...